Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Hypertension. 2016 Dec 19;69(2):304–313. doi: 10.1161/HYPERTENSIONAHA.116.08258

Table 2.

Association of kidney biomarkers with risk of incident hypertension in HIV-infected women

Unadjusted Multivariable Adjusted

Biomarker Participants
(N)
RR (95%CI) Individual Markers *
RR (95%CI)
Individual Markers
+ ACR + eGFR
RR (95%CI)
ACR
Continuous 823 1.18 (1.12, 1.25) 1.15 (1.08, 1.22) 1.13 (1.07, 1.20)
T1: < 6.9 mg/g 274 Reference Reference Reference
T2: 6.9–15 mg/g 275 1.43 (1.05, 1.96) 1.48 (1.08, 2.02) 1.49 (1.09, 2.04)
T3: >15 mg/g 274 2.11 (1.57, 2.84) 1.80 (1.33, 2.43) 1.72 (1.27, 2.33)
≤ 30 mg/g 670 Reference Reference Reference
> 30 mg/g 153 2.00 (1.54, 2.61) 1.73 (1.32, 2.26) 1.68 (1.28, 2.21)

eGFR
Continuous 823 1.16 (1.10, 1.22) 1.12 (1.06, 1.19) 1.10 (1.04, 1.17)
T1: < 81 ml/min/1.73m2 280 2.13 (1.59, 2.86) 1.73 (1.26, 2.38) 1.65 (1.20, 2.28)
T2: 81–99 ml/min/1.73m2 270 1.43 (1.05, 1.96) 1.32 (0.96, 1.81) 1.33 (0.97, 1.83)
T3: >99 ml/min/1.73m2 273 Reference Reference Reference
< 60 ml/min/1.73m2 69 1.85 (1.28, 2.67) 1.48 (1.00, 2.18) 1.32 (0.89, 1.96)
≥ 60 ml/min/1.73m2 754 Reference Reference Reference

α1m
Continuous 823 1.19 (1.08, 1.30) 1.14 (1.03, 1.26) 0.98 (0.87, 1.10)
T1§ 339 Reference Reference Reference
T2 242 1.20 (0.89, 1.62) 1.08 (0.80, 1.46) 0.98 (0.72, 1.32)
T3 242 1.55 (1.15, 2.10) 1.22 (0.90, 1.66) 0.95 (0.69, 1.32)

IL-18
Continuous 823 1.09 (0.98, 1.21) 1.11 (0.99, 1.24) 1.05 (0.94, 1.18)
T1 274 Reference Reference Reference
T2 275 1.17 (0.85, 1.59) 1.19 (0.87, 1.63) 1.13 (0.82, 1.55)
T3 274 1.15 (0.82, 1.63) 1.27 (0.89, 1.80) 1.15 (0.80, 1.64)

KIM-1
Continuous 823 1.03 (0.93, 1.14) 1.00 (0.89, 1.12) 0.90 (0.80, 1.01)
T1 274 Reference Reference Reference
T2 275 0.83 (0.61, 1.14) 0.70 (0.50, 0.97) 0.68 (0.49, 0.94)
T3 274 0.86 (0.61, 1.19) 0.78 (0.55, 1.12) 0.69 (0.48, 0.98)

NGAL
Continuous 823 1.01 (0.94, 1.10) 1.01 (0.94, 1.10) 0.96 (0.89, 1.04)
T1 274 Reference Reference Reference
T2 275 1.03 (0.77, 1.37) 1.03 (0.77, 1.38) 1.03 (0.77, 1.38)
T3 274 0.87 (0.64, 1.19) 0.90 (0.66, 1.22) 0.81 (0.59, 1.11)

L-FABP
Continuous 823 1.11 (1.05, 1.17) 1.06 (1.00, 1.13) 1.02 (0.97, 1.08)
T1 274 Reference Reference Reference
T2 275 1.32 (0.96, 1.83) 1.14 (0.82, 1.57) 1.12 (0.81, 1.55)
T3 273 1.77 (1.27, 2.47) 1.38 (0.98, 1.94) 1.23 (0.87, 1.75)

NAG
Continuous 823 1.22 (1.09, 1.35) 1.14 (1.02, 1.27) 0.97 (0.86, 1.10)
T1 274 Reference Reference Reference
T2 271 1.13 (0.81, 1.57) 0.99 (0.71, 1.39) 0.92 (0.65, 1.29)
T3 278 1.45 (1.01, 2.06) 1.19 (0.83, 1.72) 0.92 (0.63, 1.36)

AAG
Continuous 823 1.17 (1.10, 1.24) 1.13 (1.06, 1.20) 1.03 (0.96, 1.11)
T1 274 Reference Reference Reference
T2 275 1.31 (0.96, 1.79) 1.17 (0.85, 1.61) 1.10 (0.80, 1.52)
T3 274 1.78 (1.31, 2.41) 1.46 (1.07, 2.00) 1.10 (0.78, 1.54)

AAG, α1-acid-glycoprotein; ACR, albumin-to-creatinine ratio; α1m, alpha-1 microglobulin; CI, confidence interval; eGFR, estimated glomerular filtration rate by cystatin C; IL-18, interleukin 18; KIM-1, kidney injury molecule 1; L-FABP, liver fatty acid-binding protein; NAG, N-acetyl-β-D-glucosaminidase; NGAL, neutrophil-gelatinase associated lipocalin; RR, relative risk; T, tertile.

*

Adjusted for age, race/ethnicity, DM, HOMA-IR, stimulant use, CD4, HIVRNA, NRTI, HAART, HCV, and urine creatinine. Biomarkers included individually, not simultaneously

Adjusted for age, race/ethnicity, DM, HOMA-IR, stimulant use, CD4, HIVRNA, NRTI, HAART, HCV, urine creatinine, ACR, and eGFR.

Continuous eGFR is modeled per 10 ml/min/1.73m2 decrease. All other continuous predictors are modeled per doubling.

§

All below detectable